Healthcare

Addiction Biotech Cannabis Genetics Healthcare Medical Devices Pharmaceutical Science Veterinary
News Release Digital Asset Direct

News Release

SkinCell Advanced Emerges As The Leading Brand To Treat Skin Tags and Moles In The Market

Allied PR

SkinCell Advanced is a corrector serum that is deemed to be a fast and effective solution to any kinds of blemishes such as moles and skin tags. It delivers results as soon as eight hours after applying the serum on the affected area. The serum provides such products by triggering a rush of white blood cells or leukocytes in the user's body to the mole or skin tag's location. White blood cells are the immune system of our body, and they protect our bodies against foreign particles. With the white blood cells' added efforts, the serum starts removing the blemish and subsequently healing it as well. Click here to find more on SkinCell Advanced Sanguinaria Canadensis, one of the main ingredients in the SkinCell Advanced serum, is a perennial herbaceous flowering plant initially found in the eastern parts of North America. This plant, commonly known as bloodroot, was essentially used by Native Americans to treat various clinical conditions and was deemed an effective natural remedy for centuries. The Sanguinaria Canadensis flower's primary function is to stimulate the immune system and trigger white blood cells to the injured or influenced portion of the human body and begin the process of healing. The SkinCell Advanced serum uses this particular function of the flower and triggers the white blood cells to rush to the area where it is applied. Skin tags and moles often spurts up in unwanted places, and people go to new extents every day to remove them. SkinCell Advanced offers a safe and natural way to remove them without the hassle of costly surgeries and repetitive clinic appointments. On the serum application, it first alerts the immune system of the body by irritating the area containing the blemish and then triggering white blood cells to that area. The irritation is done by Zincum Muriaticum, which is known for its powerful skin irritating properties. This mineral is found in the Earth's crust and acts as a strong disinfectant and has superior antiseptic qualities. Then the serum, with the help of this mineral creates a slight inflammation over the blemish, and a small scab will form over it. The SkinCell Advanced company says that this scab will be formed after eight hours of application. Once the scab is formed over the blemish, the human immune system sees it as an injury which it has to heal and thus the body’s natural process of healing begins. The bloodroot flower extract facilitates the healing process as it helps create a concentration of white blood cells under the scab. These white blood cells will notice the scab on the user’s skin and immediately start healing it. As soon as the scab forms on the blemish, the user must stop applying the SkinCell Advanced serum and let their natural immune system do the rest of the healing. The scab which had formed over the blemish must be left alone. The user should let the scab fall off naturally. Any amount of picking at the scab or even scratching it can act as a risk of scarring. To ensure that no scars form under the scab, SkinCell Advanced advises their users not to touch the scab until it has fallen off entirely and use a Neosporin type product to limit the risk of scarring. The company has also manufactured a Repair Cream which acts as a catalyst in the healing process and ensures that the mole or skiing tag does not leave a scar. If the user does the whole process correctly, SkinCell Advanced makes sure that the blemish will disappear entirely and show no returning signs. The serum treats a wide variety of skin blemishes, including skin tags, dark moles, small warts, light moles, and even big warts. These blemishes, especially those in painful areas such as on armpits and the neck, can become frustrating to deal with. More often than not, these blemishes can become irritated from rubbing against one's clothing and cause them even more discomfort. SkinCell Advanced offers an ultimate solution to such people with their effective serum which shows quite impressive results in under eight hours. Contact Details Melissa support@jollofnews.com

February 18, 2023 11:53 AM Eastern Standard Time

Algernon Pharmaceuticals subsidiary completes first dosing in Phase 1 clinical study of DMT

Algernon Pharmaceuticals Inc.

Algernon Pharmaceuticals CEO Christopher Moreau joined Steve Darling from Proactive to share news the company’s subsidiary Algernon NeuroScience has announced it has completed the first dosing in its Phase 1 clinical study of an intravenous formulation of AP-188 or DMT. Moreau told Proactive the safety review committee has approved moving the study forward with an escalated dose after observing no safety or tolerability issues. This study will include up to 60 healthy volunteers, including both psychedelic experienced and psychedelic naïve subjects. Contact Details Proactive Canada +1 604-688-8158 na-editorial@proactiveinvestors.com

February 17, 2023 11:25 AM Eastern Standard Time

Video

Unicycive: The Company Developing Key Kidney Therapies

Unicycive Therapeutics, Inc.

Doug Jermasek, Executive Vice President, Corporate Strategy for Unicycive Therapeutics, Inc. (NASDAQ: UNCY), was recently interviewed by Benzinga. Unicycive is a biotechnology company focused on solutions for important and underserved renal diseases. The company currently has two key technologies in the development pipeline. UNI-494 works primarily to help the mitochondria in cells perform better, which in turn may help with Acute Kidney Injury (AKI). The company’s other technology, Renazorb, is currently being developed as an Investigative New Drug (IND). If approved, the drug will help patients significantly reduce their daily pill burden in the treatment of hyperphosphatemia. Watch the full interview here: Featured photo by Hal Gatewood on Unsplash Unicycive Therapeutics is a biotechnology company developing novel treatments for kidney diseases. Unicycive’s lead drug, Renazorb, is a novel phosphate binding agent being developed for the treatment of hyperphosphatemia. UNI-494 is a patent-protected new chemical entity in late preclinical development for the treatment of acute kidney injury. This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice. Contact Details Anne Marie Fields - Stern Investor Relations +1 212-362-1200 annemarie.fields@sternir.com Company Website https://unicycive.com/

February 17, 2023 10:35 AM Eastern Standard Time

Video

Nation’s Transplant System Acts to Maximize Organ Use

United Network for Organ Sharing

United Network for Organ Sharing (UNOS), the non-profit that contracts with the federal government to serve as the nation’s Organ Procurement and Transplantation Network (OPTN), is driving efforts to maximize organ acceptance and use. In its role as the OPTN, UNOS recently launched a predictive analytics tool, which adult kidney transplant programs can now use to augment decision-making and improve organ acceptance. Concurrently, the largest cohort of transplant organizations involved in an OPTN collaborative convened in Orlando, Florida recently to kick off a project focused on improving organ offer acceptance rates. The National Academies of Sciences, Engineering and Medicine (NASEM) recommended the use of predictive analytics as well as improving organ offer acceptance rates in their Feb. 2022 report on the nation’s organ donation and transplantation system. In 2022, 19.14% of all organs successfully recovered from selfless donors were not transplanted into a recipient, a statistic that UNOS is working with the entire organ donation and transplant community to improve. The new efforts signify important actions on behalf of the over 104,000 patients currently on the transplant waitlist. Predictive Analytics Tool This new tool shows physicians the predicted impact that accepting or declining a donor kidney offer could have on their patient, supplementing data already available to find the best-fit organ. This resource, offered to all adult kidney transplant programs across the country at no charge, aims to support decision-making, ultimately increasing the number of kidney transplants. Developed in collaboration with Accenture Federal Services, the tool is already providing physicians two key data points: the predicted length of time that their patient may wait for a similar kidney offer, and the patient’s likelihood of survival over the next three years without a transplant. “When we can use technology to supplement sound clinical judgement, we are best serving patients waiting for the gift of life,” said UNOS CEO Maureen McBride. “The new predictive analytics tool will help support the transplant teams making critical decisions on behalf of their patients.” Predictive analytics is the use of data, statistics and modeling to predict the likelihood of future outcomes. The NASEM report recommended using predictive data to improve organ acceptance rates in their 2022 recommendations. “Accenture is proud to be involved in the design and development of predictive analytics models which promise to improve offer acceptance in decision support tools,” said Accenture Federal Studio Design Director Ben Cannon. “We appreciate the willingness of the OPTN leadership to engage in a build-test-learn approach to address this challenge and for their close collaboration with specialists from various disciplines across both organizations - data science, human centered design, behavioral science, and technology. We are excited to continue our work and scale the predictive analytics program.” After a pilot phase that began in early 2022, UNOS used input provided by participating transplant programs to improve the tool before the national launch. An advisory panel will continue evaluating community feedback. Offer Acceptance Collaborative UNOS recently brought together transplant programs from a third of the country’s transplant hospitals to kick off the OPTN Offer Acceptance Collaborative in Orlando, Fla. The largest UNOS-led collaborative to date, this six-month effort focuses on improving responses to organ offers as well as defining and revising acceptance criteria. This collaborative will also help programs prepare for the use of a new offer acceptance metric to evaluate transplant program performance. UNOS will begin using this metric as a component of OPTN transplant program performance monitoring in July of this year. "If you look at the history of donation and transplantation, innovation is how we got here,” said Offer Acceptance Collaborative participant Deborah Maurer, who serves as Transplant Services Program Administrator at the University of Pittsburgh Medical Center. “It's our obligation to keep innovating, not just the scientific or clinical practices, but also the quality improvement processes and practices. This collaborative is a perfect example of giving the community the opportunity and mechanism to drive that innovation." Organ offers are an integral part of the nation’s organ donation and transplant system, but acceptance rates vary across the United States. The NASEM report identified offer acceptance as a “key area for improvement for transplant centers.” “UNOS is proud to convene transplant programs from across the country for this important collaborative project,” said McBride. “By strengthening our practices, constantly reevaluating what works as a community and asking tough questions about how and what we can do better, we can best serve the patients and families who rely on us.” About UNOS United Network for Organ Sharing (UNOS) is a non-profit, charitable organization that serves as the Organ Procurement and Transplantation Network (OPTN) under contract with the federal government. The OPTN helps create and define organ allocation and distribution policies that make the best use of donated organs. This process involves continuously evaluating new advances and discoveries so policies can be adapted to best serve patients waiting for transplants. All transplant programs and organ procurement organizations throughout the country are OPTN members and are obligated to follow the policies the OPTN creates for allocating organs. Contact Details United Network for Organ Sharing Anne Paschke +1 804-782-4730 anne.paschke@unos.org Company Website https://unos.org

February 16, 2023 04:25 PM Eastern Standard Time

Coya Therapeutics’ Expansion Of Exclusive Worldwide Licensing Agreement With ARscience Biotherapeutics Could Have Outsized Impact On Neurodegenerative And Autoimmune Diseases Treatments

Coya Therapeutics Inc.

By Ernest Dela Aglanu, Benzinga Houston, Texas-based Coya Therapeutics Inc. (NASDAQ: COYA) has just taken a giant leap in making effective proprietary treatments focused on certain neurodegenerative and autoimmune diseases available to more patients, as it announced the expansion of its exclusive worldwide rights for the development and commercialization of COYA 301 — the company’s low-dose IL-2 subcutaneous administration product candidate. For industry watchers, including investors, this might be very important, especially as multiple autoimmune diseases have largely unmet medical needs. A deep dive into the statistics by the American Autoimmune Related Diseases Association (AARDA) shows that an estimated ~50 million Americans have one or more autoimmune diseases. More worryingly, AARDA further said approximately 75% of those affected are women and tend to cluster in families, impacting multiple family members and generations. Autoimmune diseases are among the top 10 leading causes of death among American women. Expansion Of Its Exclusive Worldwide Rights The statistics around autoimmune diseases are certainly worrying. To help make a difference, players like Coya are actively ramping up and expanding their therapies to address the needs of the market. Coya just announced the expansion of their exclusive worldwide rights with ARScience Biotherapeutics Inc. for the development and commercialization of COYA 301, Coya’s low-dose IL-2 subcutaneous administration product candidate. Since 2020, the clinical-stage biotechnology company has been developing multiple therapeutic platforms to enhance T cell (Treg) function, including biologics and cell therapies. COYA 301 is an immunomodulatory cytokine for subcutaneous administration intended to enhance regulatory Treg function in vivo to treat the systemic and neuro-inflammation underlying certain autoimmune and neurodegenerative diseases. Under the expanded terms of the agreement with ARScience, Coya reports that it has been granted the rights to develop and commercialize COYA as a combination therapy across multiple therapeutic areas and disease conditions and as a monotherapy for various neurodegenerative disorders and autoimmune diseases. The company expatiated that these additional rights expand on the rights provided in the original license, which allowed Coya to develop and commercialize the product candidate as monotherapy for a number of neurodegenerative conditions and as a combination Treg-based therapy across multiple therapeutic areas. “We believe that Treg dysfunction is a common characteristic in certain neurodegenerative and autoimmune diseases. The expansion of the license agreement enables our development of COYA 301 in a potentially larger group of patients suffering from progressive diseases characterized by sustained inflammation,” Howard Berman, Ph.D., CEO of Coya, said in a statement. According to him, the company’s strategy is to develop COYA 301 as a monotherapy and in combination with other immunomodulatory drugs ( COYA 302 ) to potentially mitigate persistent inflammation. Carlos Banado, CEO of ARScience Biotherapeutics, also commenting on the licensing agreement, noted, “there is not currently an approved recombinant human low-dose IL-2 for therapeutic use. The development of a low-dose IL-2 formulation, delivered via a subcutaneous injection, may provide effective treatment in a wide range of diseases characterized by increased inflammation. We are confident that Coya Therapeutics has the expertise to develop and commercialize this asset in multiple indications, and we look forward to a successful collaboration.” The licensing agreement could be significant, especially as dysfunctional Tregs are the underlying cause behind numerous conditions, including neurodegenerative, metabolic and autoimmune diseases. This cellular dysfunction may lead to sustained inflammation and oxidative stress resulting in a lack of homeostasis of the immune system. Luckily, Coya says its investigational product candidate pipeline leverages multiple therapeutic modalities aimed at restoring the anti-inflammatory and immunomodulatory functions of Tregs. The company’s therapeutic platforms include Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy. The expansion of exclusive worldwide licensing agreement could give Coya an edge while having a positive impact on the global autoimmune disease diagnostics market with players like Exagen Inc. (NASDAQ: XGN), Oncimmune Holdings PLC (LON: ONC), and Retromer Therapeutics. With the global market estimated to be worth $4.7 billion in 2021 and expected to reach about $8 billion by 2027 growing at a compound annual growth rate (CAGR) of 9.3%, the company appears well positioned for continued growth. This article was originally published on Benzinga here. About Coya Therapeutics, Inc.Headquartered in Houston, TX, Coya Therapeutics, Inc. (Nasdaq: COYA) is a clinical-stage biotechnology company developing proprietary treatments focused on the biology and potential therapeutic advantages of regulatory T cells (“Tregs”) to target systemic inflammation and neuroinflammation. Dysfunctional Tregs underlie numerous conditions including neurodegenerative, metabolic, and autoimmune diseases, and this cellular dysfunction may lead to a sustained inflammation and oxidative stress resulting in lack of homeostasis of the immune system. Coya’s investigational product candidate pipeline leverages multiple therapeutic modalities aimed at restoring the anti-inflammatory and immunomodulatory functions of Tregs. Coya’s therapeutic platforms include Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy. Coya’s 300 Series product candidates, COYA 301 and COYA 302, are biologic therapies intended to enhance Treg function and expand Treg numbers. COYA 301 is a cytokine biologic for subcutaneous administration intended to enhance Treg function and expand Treg numbers in vivo, and COYA 302 is a biologic combination for subcutaneous and/or intravenous administration intended to enhance Treg function while depleting T effector function and activated macrophages. These two mechanisms may be additive or synergistic in suppressing inflammation. This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice Contact Details David S. Snyder David@coyatherapeutics.com Company Website https://coyatherapeutics.com/

February 16, 2023 09:15 AM Eastern Standard Time

Healixa Inc and WATERisLIFE Collaborate to Address the Global Water Scarcity Crisis with Global AquaDuct® Deposition Water Harvesting™ Technology

Healixa Inc.

McapmediaWire -- Healixa, Inc. (OTC: EMOR ) (“Healixa,” or the “Company”), a technology company focusing on building and acquiring innovative and disruptive technologies in the health-tech, clean water, and green-tech industries and WATERisLIFE, a global non-profit organization working to end the world water crisis, today announced their collaboration. The two organizations agreed to work together to respond to the growing water scarcity challenges in North America and internationally following recently completed demonstration of Healixa's proprietary Global AquaDuct® Deposition Water Harvesting™ Technology ("DWH ™ ") for multiple current and former US government officials and humanitarian experts. Healixa's DWH ™ technology is the world's first and only water vapor harvesting technology that can produce potable water directly from the earth's atmosphere by leveraging multiple proprietary advancements including phase-change, thermal deposition, and drawing operating power from on-grid or off-grid (solar) sources. Global AquaDuct® is a revolutionary approach to atmospheric water harvesting, providing a turnkey, sustainable, primary source of potable water in a compact form factor (only 12 sq. ft.), capable of directly addressing the significant limitations of competing technologies, to deliver substantially improved operational performance including energy efficiency, no relative humidity dependency, and constant reliable yield. Ken Surritte, Chairman, and founder of WATERisLIFE, said "Access to clean water is quickly becoming one of the most critical global challenges facing mankind. Water scarcity and droughts knows no borders and is increasingly threatening farmlands and communities in the developed world, just as it has in historically water-challenged geographies such as in Africa and the Middle East. Having seen first-hand the capabilities of Healixa's Global AquaDuct® technology, we believe this impressive and innovative solution has the potential to radically improve the lives of millions of people around the world. That is why are so excited to work with the Healixa team to showcase the impact that Global AquaDuct® can have in assisting communities around the global address their water insecurity challenges." "Healixa is dedicated to the development and commercialization of technologies that can positively impact the lives of millions. Having recently completed early-stage commercialization and testing of our Global AquaDuct® water harvesting technology, we are confident in its unmatched capabilities and potential. We are pleased to work alongside leading humanitarian organizations such as WATERisLIFE as we expand the awareness of our unique DWH ™ technology and advance our commercialization efforts with potential customers," added Ian Parker, Chairman and CEO of Healixa. About Healixa, Inc. Healixa is a technology company focusing on building and acquiring innovative and disruptive technologies in the health-tech, clean water generation and green-tech industries. Healixa embraces innovation by combining its intellectual properties, patents, strategic collaborations, and partnerships to create a "LaunchPad" of disruptive sustainable products. For more information, visit www.healixa.com. About WATERisLIFE WATERisLIFE is a 501 (c)(3) public charity bringing life-changing water solutions to the areas of the world that need it the most. For nearly two decades, WATERisLIFE has been working with the UN and the sustainability goals established by the UN for bringing safe water around the world. We aim to solve the world water crisis through better WASH (water, sanitation, and hygiene) programs in developing countries. WATERisLIFE brings cutting-edge technologies to the 47 countries we have been doing projects in. WATERisLIFE water, sanitation, and hygiene solutions have reached more than 60,000,000 people worldwide since inception. For more information, visit the website at www.WATERisLIFE.com Safe Harbor Statement Certain statements contained in this press release may constitute forward-looking statements. For example, forward-looking statements are used when discussing our expected research and development programs, and more. These forward-looking statements are based only on current expectations of management and are subject to significant risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements, including but not limited to the risks and uncertainties related to the progress, timing, cost, and results of Partnerships and product development programs; difficulties or delays in obtaining regulatory approval or patent protection; and competition from other companies. Except as otherwise required by law, Healixa, Inc. undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. Healixia Contact: Bret Hedges SVP of Strategic Partnerships 833-432-5492 Bret@healixa.com WATERisLIFE Contact: Director of Communications Cote@WATERisLIFE.com Contact Details Healixia Bret Hedges +1 833-432-5492 Bret@healixa.com WATERisLIFE Director of Communications Cote@WATERisLIFE.com

February 16, 2023 08:52 AM Eastern Standard Time

Faron Pharmaceuticals CMO "looking forward to a year filled with good data for the patients"

Faron Pharmaceuticals Oy

Faron Pharmaceuticals Limited (AIM:FARN, OTC:FPHAF) chief medical officer Marie-Louise Fjällskog updates Proactive's Thomas Warner the clinical-stage biopharmaceutical company's wholly-owned precision immunotherapy asset, Bexmarilimab. Fjällskog says that she's "looking forward to a year filled with good data for the patients." Contact Details Proactive UK Ltd Proactive UK Ltd +44 20 7989 0813 uk@proactiveinvestors.com

February 16, 2023 07:10 AM Eastern Standard Time

Video

Arecor Therapeutics "confident" in collaboration pipeline after another new deal

Arecor Therapeutics PLC

Arecor Therapeutics PLC (AIM:AREC) CEO Sarah Howell speaks to Proactive's Thomas Warner after announcing the biopharma group has signed another collaboration deal with a top five pharmaceutical partner. The deal is the eighth of its type since the group’s listing in May 2021 and Howell says that she’s “confident” that the company will be announcing more such collaborations in the coming months. Contact Details Proactive UK Ltd +44 20 7989 0813 uk@proactiveinvestors.com

February 16, 2023 05:55 AM Eastern Standard Time

Video

News Release

BioHarvest Sciences to begin human clinical study with multiple sclerosis-related optic neuritis

BioHarvest Sciences Inc.

BioHarvest Sciences CEO Ilan Sobel joined Proactive's Steve Darling to share news the company has agreed to a collaboration with the International Neurorehabilitation Institute in Maryland to perform a clinical trial to assess the capacity of the company’s red grape cell (RGC) composition to promote eye health. RGC is produced using BioHarvest's Botanical-Synthesis technology. Sobel told Proactive the study will be an open-label clinical study to evaluate the impact of RGC on multiple sclerosis-related optic neuritis driven by inflammation. The Multiple Sclerosis Foundation estimates more than 1 million people in the US and about 2.5 million people worldwide have been diagnosed with MS. Contact Details Proactive Investors Canada +1 604-688-8158 na-editorial@proactiveinvestors.com

February 15, 2023 01:21 PM Eastern Standard Time

Video

1 ... 160 161 162 163 164 ... 309